相似文献
1
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.
Haematologica. 2009 Sep;94(9):1198-202. doi: 10.3324/haematol.2009.009274.
2
Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Curr Hematol Malig Rep. 2013 Mar;8(1):7-13. doi: 10.1007/s11899-012-0146-x.
3
Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Leuk Lymphoma. 2010 Aug;51(8):1382-5. doi: 10.3109/10428194.2010.496017.
4
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Expert Opin Investig Drugs. 2017 May;26(5):633-650. doi: 10.1080/13543784.2017.1313230. Epub 2017 Apr 17.
5
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
Cancer. 2011 Sep 1;117(17):3999-4008. doi: 10.1002/cncr.25983. Epub 2011 Feb 24.
6
Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Leuk Lymphoma. 2007 May;48(5):866-9. doi: 10.1080/10428190601126636.
7
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Expert Opin Investig Drugs. 2011 Feb;20(2):273-86. doi: 10.1517/13543784.2011.546343. Epub 2011 Jan 10.
8
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
J Clin Oncol. 2006 Dec 1;24(34):5343-9. doi: 10.1200/JCO.2005.05.0401. Epub 2006 Nov 6.
9
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Blood. 2012 Aug 16;120(7):1412-21. doi: 10.1182/blood-2012-02-411678. Epub 2012 Apr 30.
10
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Eur J Haematol. 2013 Apr;90(4):340-4. doi: 10.1111/ejh.12068. Epub 2013 Feb 14.
引用本文的文献
1
CCL2 mediated IKZF1 expression promotes M2 polarization of glioma-associated macrophages through CD84-SHP2 pathway.
Oncogene. 2024 Aug;43(36):2737-2749. doi: 10.1038/s41388-024-03118-w. Epub 2024 Aug 7.
2
Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2.
Biology (Basel). 2023 Oct 16;12(10):1337. doi: 10.3390/biology12101337.
3
Targeting the tumor microenvironment in chronic lymphocytic leukemia.
Haematologica. 2021 Sep 1;106(9):2312-2324. doi: 10.3324/haematol.2020.268037.
4
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective.
Haematologica. 2021 May 1;106(5):1234-1243. doi: 10.3324/haematol.2020.267914.
5
Novel Therapy Approaches to Follicular Lymphoma.
Drugs. 2021 Mar;81(4):453-469. doi: 10.1007/s40265-020-01446-1.
6
IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner.
Oncotarget. 2018 Feb 7;9(17):13125-13138. doi: 10.18632/oncotarget.24442. eCollection 2018 Mar 2.
7
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15.
8
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Clin Cancer Res. 2018 Jan 1;24(1):106-119. doi: 10.1158/1078-0432.CCR-17-0344. Epub 2017 Oct 23.
9
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Cancer Immunol Res. 2016 Aug;4(8):698-707. doi: 10.1158/2326-6066.CIR-15-0291. Epub 2016 Jun 10.
10
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Br J Haematol. 2016 Apr;173(2):283-91. doi: 10.1111/bjh.13957. Epub 2016 Feb 23.
本文引用的文献
1
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Haematologica. 2009 Sep;94(9):1266-73. doi: 10.3324/haematol.2009.005835.
2
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6250-5. doi: 10.1073/pnas.0901166106. Epub 2009 Mar 30.
3
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Br J Haematol. 2009 Mar;144(6):848-55. doi: 10.1111/j.1365-2141.2008.07548.x. Epub 2009 Jan 12.
4
Stem cell transplantation in chronic lymphocytic leukemia.
Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):53-8. doi: 10.1016/j.bbmt.2008.10.022.
5
Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.
J Clin Oncol. 2008 Oct 10;26(29):4851-2; author reply 4852-3. doi: 10.1200/JCO.2008.18.2857. Epub 2008 Sep 8.
6
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Blood. 2008 Dec 15;112(13):5180-9. doi: 10.1182/blood-2008-01-133108. Epub 2008 Sep 4.
7
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Clin Cancer Res. 2008 Jul 15;14(14):4650-7. doi: 10.1158/1078-0432.CCR-07-4405.
8
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
J Clin Invest. 2008 Jul;118(7):2427-37. doi: 10.1172/JCI35017.
9
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
J Clin Oncol. 2008 May 20;26(15):2519-25. doi: 10.1200/JCO.2007.13.9709. Epub 2008 Apr 21.
10
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Blood. 2008 Aug 15;112(4):975-80. doi: 10.1182/blood-2008-02-140582. Epub 2008 Apr 14.
Zotero 插件